Skip to main content
AGEN
NASDAQ Life Sciences

Agenus CEO Garo Armen Appointed Interim CFO; Austin Charette Named Principal Accounting Officer

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$4.68
Mkt Cap
$159.159M
52W Low
$1.38
52W High
$7.34
52W Position info
239% above low
Off High info
36% below high
Rel. Volume info
2.1× avg
Market data snapshot near publication time

AGEN has more than doubled off its 52-week low of $1.38 on elevated volume (2.1× avg).

Summary

Agenus Inc. announced that Chairman and CEO Dr. Garo Armen will also serve as interim Chief Financial Officer, while Senior Director Austin Charette has been promoted to Principal Accounting Officer.


Key Events · Executive and Board Changes · AGEN

  • CEO Appointed Interim CFO

    Dr. Garo Armen, the current Chairman and Chief Executive Officer, has been appointed to serve as the company's interim Chief Financial Officer and Principal Financial Officer, effective January 8, 2026.

  • Principal Accounting Officer Appointed

    Austin Charette, previously Senior Director, Financial Reporting and Compliance, has been appointed as the company's Principal Accounting Officer, effective January 8, 2026.

  • CEO Compensation Unchanged

    No new arrangements or modifications to existing compensation were made for Dr. Armen; he continues to receive base salary and potential bonus payments in Agenus stock rather than cash.


Analysis · AGEN · Life Sciences

Agenus Inc. announced significant changes to its financial leadership. The appointment of Chairman and CEO Dr. Garo Armen as interim Chief Financial Officer signals direct oversight and commitment from the top executive in managing the company's finances. His extensive background and continued acceptance of stock-based compensation for salary and bonus reinforce this commitment. While the interim nature suggests a search for a permanent CFO, Dr. Armen's dual role provides immediate stability. Additionally, the promotion of Austin Charette to Principal Accounting Officer from within the company ensures continuity in financial reporting and compliance.

At the time of this filing, AGEN was trading at $4.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $159.2M. The 52-week trading range was $1.38 to $7.34. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AGEN - Latest Insights

AGEN
Jul 13, 2026, 6:43 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.95
Real-time Price: $6.58 info
Change: +$2.63 (+67%) info
Market Cap: $295.365M info
AGEN
Jul 13, 2026, 6:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.87
Real-time Price: $6.58 info
Change: +$2.71 (+70%) info
Market Cap: $295.365M info
AGEN
Jul 06, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.41
Real-time Price: $6.58 info
Change: +$3.17 (+93%) info
Market Cap: $295.365M info
AGEN
Jun 23, 2026, 10:14 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.15
Real-time Price: $6.58 info
Change: +$3.43 (+109%) info
Market Cap: $295.365M info
AGEN
May 15, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.48
Real-time Price: $6.58 info
Change: +$3.10 (+89%) info
Market Cap: $295.365M info